South Dakota Biotech Association: Sioux Falls Company Developing Potential Treatment for Coronavirus
March 16, 2020
March 16, 2020
SIOUX FALLS, South Dakota, March 16 -- The South Dakota Biotech Association issued the following news release:
SAB Biotherapeutics, a Sioux Falls clinical-stage biopharmaceutical company that developed a first-of-its-kind therapeutic approach, is rapidly working to develop what its CEO said could be the first treatment specifically designed to target the new coronavirus known as SARS-CoV-2, the virus responsible for COVID-19.
SAB's DiversitAb(TM) platform, which leverag . . .
SAB Biotherapeutics, a Sioux Falls clinical-stage biopharmaceutical company that developed a first-of-its-kind therapeutic approach, is rapidly working to develop what its CEO said could be the first treatment specifically designed to target the new coronavirus known as SARS-CoV-2, the virus responsible for COVID-19.
SAB's DiversitAb(TM) platform, which leverag . . .